Ahmed Abouabdellah,Aude Fayol,Corinne Veronique,Julien Vache,Mourad Saady,Nathalie Chereze,Philippe Yaiche
申请号：
BRPI0921057
公开号：
BRPI0921057A2
申请日:
2009.11.13
申请国别(地区):
BR
年份:
2018
代理人:
摘要：
Compound corresponding to general formula (I): in which R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy or NR8R9 group； n is an integer equal to 1, 2 or 3 and m is an integer equal to 1 or 2； A is a covalent bond or a C1-8-alkylene group； R1 is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl group, this group being optionally substituted； R3 is a hydrogen or fluorine atom, a C1-6-alkyl group or a tritluoromethyl group； R4 is a group selected from furanyl, pyrrolyl, thienyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, imidazole, triazolyl, tetrazolyl, oxazolone, oxazolidinone, isoxazolone, isoxazolidinone, isothiazolone, isothiazolidinone, imidazolone, imidazolidinone, pyrazolone, pyrazolidinone, oxadiazolone, thiadiazolone and triazolone, this group being optionally substituted； in the form of a base or of an addition salt with an acid. Therapeutic use.
